Investors - Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):

 

Our websites

 
 

Middle area:

Sales by business and region

Net sales reported by Sanofi are composed of net sales generated by the pharmaceuticals, vaccines and animal health businesses.

On a geographic basis, the Group’s net sales are broken down between Western Europe, United States, Emerging Markets and Rest of the world (including Japan) since 2010.

2012 net sales

2012 sales growth figures are stated "at constant exchange rates".

2012 net sales
€ millionQ1
2012		Q2
2012		Q3
2012		Q4
2012		2012%
Change
(vs. 2011)
Pharmaceuticals7,3167,5117,0407,00428,871-0.4%
Vaccines6177831,4811,0163,897+5.7%
Animal Health5785765195062,179+3.1%
Total sales8,5118,8709,0408,52634,947+0.5%
United States2,6002,7952,9982,48010,873+0.7%
Western Europe*2,2252,1362,0451,9298,335–9.3%
Emerging Markets**2,6242,8232,8212,87711,145+8.3%
of which Eastern Europe,
Russia and Turkey		6576706677272,721+2.1%
of which Asia6657167517092,841+10.1%
of which Latin America7888878928683,435+11.3%
of which Africa2522552472641,018+8.3%
of which Middle East2272672312761,001+12.2%
Rest of the World***1,0621,1161,1761,2404,594+2.5%
of which Japan7337968329133,274+6.6%
 

* France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark

** World less USA, Canada, Western Europe, Japan, Australia and New Zealand

*** Japan, Canada, Australia and New Zealand

2012 net sales by product

2012 net sales by product
€ millionQ1
2012		Q2
2012		Q3
2012		Q4
2012		2012%
Change
(vs. 2011)
Lantus®1,1181,2281,2791,3354,960+19.3%
Apidra®52565765230+16.8%
Amaryl®103110106102421–8.0%
Insuman®32333436135+3.0%
Total Diabetes1,3111,4361,4861,5495,782+16.7%
Taxotere®150159129125563–41.9%
Eloxatin®38437512968956–17.3%
Jevtana®54655660235+20.2%
Zaltrap®
-
-
71825
-
Mozobil®NCNC262596
-
Other Oncology153125138121519
-
Total Oncology7417514854172,394–14.3%
Lovenox®5264894374411,893–12.0%
Plavix®5055535055032,066–4.6%
Aprovel®3073342982121,151–13.3%
Allegra®182126110135553–9.5%
Stilnox®/ Ambien®/ Ambien CR®/ Myslee®125129126117497–4.5%
Copaxone®2400024–94.7%
Depakine®100102105103410+3.1%
Tritace®87938382345–8.3%
Multaq®63646563255–8.0%
Xatral®33363229130–37.0%
Actonel®36363230134–21.6%
Nasacort®1919151871–35.8%
Renagel®/ Renvela®147165164177653-
Synvisc®/ Synvisc1®781068990363-
Aubagio®   77-
Cerezyme®149150163171633-
Myozyme®112113116121462-
Fabrazyme®47748784292-
Other Rare Diseases products929710498391-
New Genzyme4004344704811,785-
Other Rx Drugs1,3881,4321,3261,3675,513–9.1%
Consumer Health Care8057387337323,008+9.9%
Generics4394684794581,844+5.0%
Total Pharmaceuticals7,3167,5117,0407,00428,871–0.4%

Detail of Vaccines net sales:

Detail of Vaccines 2012 net sales
€ millionQ1
2012		Q2
2012		Q3
2012		Q4
2012		2012%
Change
(vs. 2011)
Polio/Pertussis/Hib2452733203461,184+5.0%
Influenza8980608107884–0.2%
Meningitis/Pneumonia73129230218650+18.0%
Adult Boosters87146140123496+0.0%
Travel & Other Endemics7710083104364–4.9%
Other4655100118319+31.8%
Total Vaccines6177831,4811,0163,897+5.7%

Detail of Animal Health net sales:

Detail of Animal Health 2012 net sales
€ millionQ1
2012		Q2
2012		Q3
2012		Q4
2012		2012% Change
(vs. 2011)
Frontline® and other fipronil products240228178129775–3.4%
Vaccines165180172213730+7.6%
Avermectin11410710993423+7.8%
Other59616071251+3.9%
Total Animal Health5785765195062,179+3.1%
 

Further information on 2012 net sales:

  
Top of page

2011 net sales

2011 sales growth figures are stated “at constant exchange rates”.

2011 net sales
€ millionQ1 2011Q2 2011Q3 2011Q4 2011FY 2011% Change
(vs. FY 2010)
Pharmaceuticals6,5837,1476,9407,22027,890+6.7%
Vaccines6027061,3438183,469-5.5%
Animal Health5944964704702,030+4.3%
Total sales7,7798,3498,7538,50833,389+5.3%
Western Europe*2,2512,3802,2912,2089,130-4.0%
United States2,1652,4162,9022,4759,957+6.8%
Emerging Markets**2,3862,5332,5652,64910,133+10.1%
of which Eastern Europe and Turkey6636876496672,666+3.7%
of which Asia (excl. the Pacific region)5715816316342,416+16.6%
of which Latin America6847988028283,111+11.8%
of which Africa232238240239949+9.7%
of which Middle East213204217237872+8.6%
Rest of the World***9771,0209951,1764,169+13.8%
of which Japan6656996578402,865+20.2%
 

* France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark

** World less North America (USA, Canada), Western Europe, Japan, Australia and New Zealand

*** Japan, Canada, Australia and New Zealand

Detail of Pharmaceuticals net sales:

Detail of Pharmaceuticals 2011 net sales
€ millionQ1 2011Q2 2011Q3 2011Q4 2011FY 2011% Change
(vs. FY 2010)
Lantus®9259699681,0543,916+15.0%
Apidra®49535335190+9.6%
Amaryl®108109106113436-7.9%
Insuman®31333236132-0.8%
Total Diabetes1,1131,1681,1611,2424,684+12.0%
Lovenox®5835361,1194982,111-23.4%
Plavix®4845109945292,040-2.9%
Taxotere®382204186150922-57.0%
Aprovel®3203433143141,291-2.4%
Eloxatin®1882483103251,071+160.9%
Multaq®63686664261+56.4%
Jevtana®48484547188+135,4%
Stilnox®/ Ambien®/ Ambien CR®/ Myslee®116116121137490-41.4%
Allegra®216119103142580-8.6%
Copaxone®11411911786436-15.4%
Tritace®99959388375-6.3%
Depakine®9610091101388+5.4%
Xatral®65643437200-30.7%
Actonel®48433937167-29.8%
Nasacort®43311418106-41.8%
Other products1,4791,4611,3921,4415,773-3.4%
Consumer Health Care7126446656452,666+22.8%
Generics4144344104881,746+16.2%
Genzyme-7967688312,395ns
Total Pharmaceuticals6,5837,1476,9407,22027,890+6.7%

Detail of Vaccines net sales:

Detail of Vaccines 2011 net sales
€ millionQ1 2011Q2 2011Q3 2011Q4 2011FY 2011% Change
(vs. FY 2010)
Polio/Pertussis/Hib
(incl. Pentacel® and Pentaxim®)		2272672563251,075+12.0%
Influenza
(incl. Vaxigrip® and Fluzone®)		1015760266826-33.2%
Meningitis/Pneumonia
(incl. Menactra®)		62121212115510+2.3%
Adult Boosters
(incl. Adacel®)		96110122137465+7.3%
Travel & Other Endemics819098101370-1.6%
Other vaccines35615374223+37.8%
Total Vaccines6027061,3438183,469-5.5%

Detail of Animal Health net sales:

Detail of Animal Health 2011 net sales
€ millionQ1 2011Q2 2011Q3 2011Q4 2011FY 2011% Change
(vs. 2010)
Frontline® and other fipronil products270189173132764+0.9%
Vaccines166159147190662+7.2%
Avermectin105938886372+6.5%
Other53556262232+4.4%
Total Animal Health5944964704702,030+4.3%
 

Further information on 2011 net sales:

  
Top of page

2010 net sales

2010 sales growth figures are stated “at constant exchange rates”. When relevant, sales growth figures “on a constant structure basis and at constant exchange rates” are indicated between brackets.

2010 net sales
€ millionQ1 2010Q2 2010Q3 2010Q4 2010FY 2010% Change
(vs. FY 2009)
Pharmaceuticals6,4417,0356,5956,50526,576-1.6%
(-3.6%)
Vaccines9447481,2268903,808+4.8%
(+3.8)
Total sales7,3857,7837,8217,39530,384-0.8%
(-2.7%)
Western Europe*2,4112,2522,1882,1468,997-8.8%
United States1,9472,4132,4992,1098,968-8.4%
Emerging Markets**2,2742,2862,3142,2019,075+16.3%
of which Eastern Europe and Turkey6416676726322,612+10.0%
of which Asia (excl. the Pacific region)4685015135011,983+14.2%
of which Latin America7536686836312,735+32.4%
of which Africa196220221209846+4.0%
of which Middle East193195199202789+19.6%
Rest of the World***7538328209393,344+7.7%
of which Japan5095525236412,225+9.1%
 

* France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark

** World less North America (USA, Canada), Western Europe, Japan, Australia and New Zealand

*** Japan, Canada, Australia and New Zealand

Further information on 2010 net sales:

  
Top of page

2009 net sales

2009 sales growth figures are stated “at constant exchange rates”. When relevant, sales growth figures “on a constant structure basis and at constant exchange rates” are indicated between brackets.

2009 net sales
€ millionQ1 2009Q2 2009Q3 2009Q4 20092009% Change
(vs. 2008)
Pharmaceuticals6,4806,7266,3546,26325,823+3.7%
Vaccines6277121,0461,0983,483+19.2%
Total sales7,1077,4387,4007,36129,306+5.3%
Europe2,9483,0793,0502,98212,059+3.2%
United States2,2952,4382,4412,2529,426+2.8%
Other countries1,8641,9211,9092,1277,821+12.1%
 

Further information on 2009 net sales:

  
Top of page

Right area:

Stock Market

Your services

 

IAS19R

Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1st, 2013

 

Income Statements

Merial

 

Historical Consolidated Net Sales

 

Business Net Income

   

Further information

Event

 

Publications

 

SEC Filings

 

Tools menu:

© Sanofi 2004-2013 - All rights reserved - Update: February 13, 2013

Site complies with W3C WCAG 2.0 (new window, in english)